EDX EDX Medical Group Plc

 
TIDMEDX 
 
This announcement contains Inside Information as stipulated under the UK 
version of the Market Abuse Regulation No 596/2014 which is part of English law 
by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of 
this announcement via a regulatory information service, this information is 
considered to be in the public domain. 
 
                          LONDON: 21st November 2022 
 
                             EDX Medical Group Plc 
 
                                 (The Company) 
 
      EDX Medical Group Plc announces European Cancer Biomarker Programme 
      collaboration with Tianjin Bioscience Diagnostic Technology Co. Ltd 
 
EDX Medical Group plc, ("EDX Medical" or the "Company"), which develops 
innovative digital diagnostic products and services for cancer, heart disease, 
neurology and infectious disease testing, today announces a collaborative 
cancer biomarker programme that will improve access to cost-effective and 
reliable tests for a range of cancers in the UK and Europe. 
 
The programme is a result of a partnership between the Company and 
Tianjin Bioscience Diagnostic Technology Co. Ltd ("Bioscience"), an 
internationally active, ISO 13485-certified research-based manufacturer of 
diagnostic products and reagents. The Company has been selected by Bioscience 
as its lead partner to validate and commercialise its suite of internationally 
recognised cancer biomarkers in Europe. 
 
The programme will encompass the validation and clinical deployment of 
Bioscience's digital chemiluminescence immunoassay technology for an initial 10 
cancer biomarkers, including the key glycoprotein Carbohydrate Antigens: 
CA-15-3, CA19-9, CA-125, and CA-72-4. These biomarkers are recognised as 
important tools to improve the clinical management of a range of cancers and 
will be deployed both individually and in combination using the Bioscience 
automated analysers. 
 
As part of the collaborative programme, the Company will conduct validation 
studies and submit data on individual tests to UK and EU Authorities for 
regulatory approval.   Under the collaboration, Bioscience has installed two 
automated digital chemiluminescence immunoassay instruments at the Company's 
laboratory in Cambridge, UK, with initial capability to process up to 250,000 
tests per annum, and  providing rapid response times for UK clients. 
 
Dr Mike Hudson, CEO of EDX Medical, said: "We are delighted to announce this 
collaboration with Bioscience, which will accelerate access to these highly 
reliable, affordable laboratory tests for doctors, patients and cancer 
survivors in the UK and Europe. The automation and combination of tests means 
improved flexibility, enhanced data and rapid delivery of test results". 
 
"This capability is an important building block in our strategy to offer one of 
the most complete suites of cancer tests in the UK, supported by definitive 
functional genomics from our Cambridge laboratory. This partnership will bring 
forward our commercialisation plans for our cancer products." 
 
Professor Sir Chris Evans, Founder of EDX Medical, said: "I'm delighted that a 
high-quality company such as Bioscience has selected EDX Medical to partner and 
pioneer the launch of their latest cancer tests across the UK and Europe, 
particularly at a time when the post-pandemic world grapples with huge backlogs 
of cancer patients and the need for fast, effective diagnostic products and 
services." 
 
Lina Lee, Head of International Sales at Tianjin Bioscience 
Diagnostic Technology Co. Ltd, said: "We are very pleased to be working with 
EDX Medical Group, a fast-growing and innovative partner, to lead the 
validation and commercialisation of our oncology laboratory tests in the UK and 
Europe, along with future co-development of new tests". 
 
Notes for Editors: 
 
This announcement and collaboration is part of an expanding programme of cancer 
diagnostics tests and services being prepared for launch in the UK and Europe 
by EDX Medical Group Plc. 
 
CA 15-3 is primarily used to monitor breast cancer and its response to 
treatment. 
 
CA 125 is useful to monitor women who may be at increased risk of cancer of the 
uterus, cervix, fallopian tubes, such as those with a family history of ovarian 
cancer. 
 
CA 19-9 is one of the most reliable biomarkers for pancreatic cancer, capable 
of identifying the recurrence of cancer before radiographic or clinical 
findings by up to 7 months. 
 
CA 72-4 exhibits excellent specificity enabling the differential diagnosis of 
gastrointestinal cancer from other GI-based inflammatory disease. When combined 
with CEA and CA19-9, CA72-4 can provide valuable information on the state of 
lymphatic metastasis, vascular invasion, nerve infiltration, tumour size and 
degree of tumour differentiation, guiding clinical treatment options. 
 
About EDX Medical Group 
 
EDX Medical develops and delivers innovative digital diagnostic products and 
services for cancer, heart disease, neurology and infectious disease testing, 
helping to predict disease risk, inform clinical decision-making and accelerate 
the development of new medicines. The company is listed on the Access Segment 
of the AQSE Growth Market (TIDM: EDX). 
 
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and 
life sciences entrepreneur with more than 30 years of experience in the sector, 
specialising in cancer treatments and diagnostics. 
 
By translating clinical insights into pragmatic solutions combining advanced 
biological and digital technologies, EDX Medical seeks to cost-effectively 
improve the detection of disease risk and personalise disease management in a 
timely fashion. Early disease detection and risk prediction is the most 
impactful way of reducing deaths and lowering the future costs of healthcare 
provision globally. 
 
 
EDX Medical operates a molecular biology and diagnostics laboratory in 
Cambridge, UK, from which it performs research & development (R&D), provides 
testing and genomic sequencing services, undertakes quality assurance and has 
established expertise in the design, development, validation and sourcing of 
diagnostic tests at commercial scale. Key tests performed in this laboratory 
have been audited by the United Kingdom Accreditation Service (UKAS) and 
accredited to ISO 15189. 
 
www.edxmedical.co.uk 
 
The Directors of the Company accept responsibility for the contents of this 
announcement. 
 
Enquiries: 
 
Company                                       +44 (0)20 7710 0020 
Dr Michael Hudson, CEO 
 
AQSE Corporate Advisor                        +44 (0)20 7220 9795 
Peterhouse Capital Limited 
Guy Miller 
Mark Anwyl 
 
Public Relations on behalf of the Company     +44 (0)20 7710 0020 
Ramsay Smith, Media House International       +44 (0) 7788 414856 
Limited                                       ramsay@mediahouse.co.uk 
 
www.bioscience-tj.com 
 
Media contact: Tianjin Bioscience Diagnostic Technology Co.Ltd.+86 22 84849080, 
email: sales@bioscience-tj.com 
 
 
 
END 
 
 

(END) Dow Jones Newswires

November 21, 2022 02:00 ET (07:00 GMT)

Grafico Azioni EDX Medical (AQSE:EDX)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni EDX Medical (AQSE:EDX)
Storico
Da Giu 2023 a Giu 2024